Research programme: CD47 antigen/SIRPalpha protein modulators - Trillium Therapeutics

Drug Profile

Research programme: CD47 antigen/SIRPalpha protein modulators - Trillium Therapeutics

Alternative Names: CD47Fc; TTI-622

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator The Hospital for Sick Children; University Health Network
  • Developer The Hospital for Sick Children; Trillium Therapeutics Inc; University Health Network
  • Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action CD47 antigen inhibitors; SIRPA protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer
  • Discontinued Transplant rejection

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Combination therapy) in Canada (Parenteral)
  • 13 Nov 2014 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia released by Trillium Therapeutics
  • 07 Aug 2014 Research programme: CD47 antigen/SIRPalpha protein modulators - Trillium Therapeutics is available for licensing and collaboration as of 18 Aug 2014. www.trilliumtherapeutics.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top